Trial Profile
A Phase 1,Randomized, Double--Blind, Placebo-Controlled Study Assessing the Safety and Tolerability, the Pharmacodynamics and Pharmacokinetics of Single-Ascending and Repeated Doses of Inhaled TPI 1100 in Healthy Subjects.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs TPI 1100 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 15 Mar 2011 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Jun 2009 New trial record